相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Edward M. Vital et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
Ian N. Bruce et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2022)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study
David M. Phillippo et al.
STATISTICS IN MEDICINE (2020)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
DA Isenberg et al.
RHEUMATOLOGY (2005)
分享论文
